All In Biotech

Drug Trial Radar · NCT05208944

THIO Sequenced With Cemiplimab in Advanced NSCLC

A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced With Cemiplimab (LIBTAYO®) in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 227 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

227

Planned (sponsor's estimate)

Start

Jun 8, 2022

Primary completion

Sep 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Maia BiotechnologyIndustry
Sponsor type
Industry
First posted
Jan 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

THIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®). THIO is preferentially incorporated into telomeres sequence in telomerase-positive cells leading to rapid telomere uncapping, genomic instability, and cell death. Cemiplimab is a programmed cell death protein 1 (PD-1) inhibitor recently approved as a first-line treatment for patients with locally advanced or metastatic NSCLC with 50% or more PD-L1 expression. It is hypothesized that THIO administration prior to cemiplimab would restore tumor responses to immunotherapy in subjects who either developed resistance or relapsed after receiving first line treatment with an immune check point inhibitor.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • 6-Thio-2'-DeoxyguanosineDrug

    small molecule telomere targeting agent

  • CemiplimabDrug

    programmed cell death protein 1 (PD-1) inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the safety and tolerability of THIO administered in sequence with cemiplimab in subjects with advanced NSCLCTime frame: Up to 2 years
  2. To assess the efficacy of THIO administered in sequence with cemiplimab in subjects with advanced NSCLCTime frame: Up to 2 years
  3. To assess the efficacy of THIO administered in sequence with cemiplimab in subjects with advanced NSCLCTime frame: Up to 2 years
  4. To determine the safety and tolerability of THIO administered in sequence with cemiplimab in subjects with advanced NSCLCTime frame: Up to 2 years
  5. To determine the safety and tolerability of THIO administered in sequence with cemiplimab in subjects with advanced NSCLCTime frame: Up to 2 years

Locations

40 sites in 8 countries. Site status is shown where the registry gives one.

  • Central Alabama Research

    Birmingham, Alabama

  • Summit Health

    Florham Park, New Jersey

  • Sunshine Coast Haematology and Oncology Clinic

    Buderim, Queensland, Australia

  • Cancer Research SA

    Adelaide, South Australia, Australia

  • St. Vincent Hospital Melbourne

    Fitzroy, Victoria, Australia

  • MHAT "HEART AND BRAIN" EAD Clinic of Medical Oncology

    Pleven, Bulgaria

  • MC Synexus Sofia EOOD

    Sofia, Bulgaria

  • MHAT "Serdika" EOOD

    Sofia, Bulgaria

  • UMHAT "Sofiamed"

    Sofia, Bulgaria

  • LTD High Technology Hospital Medcenter

    Batumi, Georgia

  • Israel-Georgian Medical Research Clinic Healthycore LTD

    Tbilisi, Georgia

  • LTD "New Hospitals"

    Tbilisi, Georgia

  • Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic LLC

    Tbilisi, Georgia

  • Todua Clinic LLC

    Tbilisi, Georgia

  • Semmelweis Egyetem Pulmonologiai Klinika

    Budapest, Hungary

  • Országos Korányi Pulmonológiai Intézet

    Budapest, Hungary

  • Orszagos Onkologiai Intezet

    Budapest, Hungary

  • Debreceni Egyetem Klinikai Kozpont, Tudogyogyaszati Klinika

    Debrecen, Hungary

  • Bács-Kiskun Megyei Oktatókórház, Onkoradiológiai Központ

    Kecskemét, Hungary

  • Mátrai Gyógyintézet

    Mátraháza, Hungary

  • Hetenyi Geza Korhaz, Onkologiai Kozpont

    Szolnok, Hungary

  • Tüdőgyógyintézet Törökbálint, Onkológiai Osztályc

    Törökbálint, Hungary

  • Centrum Onkologii im. prof. F. Lukaszczyka

    Bydgoszcz, Poland

  • Krakowski Szpital Specjalistyczny im. Jana Pawla II Oddzial Onkologii z Pododdzialem Diagnostyki Nowotworow Klatki Piersiowej

    Krakow, Poland

  • Centrum Terapii Współczesnej J. M. Jasnorzewska

    Lodz, Poland

  • NeuroMed

    Lublin, Poland

  • Med Polonia Sp z o.o.

    Poznan, Poland

  • Centrum Medyczne Mrukmed

    Rzeszów, Poland

  • Centrum Medyczne Pratia

    Skorzewo, Poland

  • Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, Oddzial Chemioterapii Nowotworow

    Torun, Poland

  • NZOZ FORMED 2 Sp. z o.o.

    Oświęcim, Oswiecim, Poland

  • Taipei Veterans General Hospital

    Taipei, Beitou District, Taiwan

  • Chang-Gung Memorial Hospital - Linko

    Taoyuan City, Guishan District, Taiwan

  • Tri-Service General Hospital

    Taipei, Neihu District, Taiwan

  • Chang-Gung Memorial Hospital

    Kaohsiung City, Niaosong District, Taiwan

  • Taipei Tzu Chi Hospital

    New Taipei City, Xindian Dist, Taiwan

  • Taipei Medical University Hospital

    Taipei, Xinyi District, Taiwan

  • National Taiwan University Hospital

    Taipei, Zhongzheng District, Taiwan

  • Liv Hospital Ankara, Medikal Onkoloji Bilim Dalı

    Ankara, Turkey (Türkiye)

  • İstinye Üniversitesi Hastanesi Liv Hospital Bahçeşehir

    Istanbul, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.